What question did this study set out to answer?

To evaluate the diffusion rate of eight newly launched drugs during their initial market phase and determine differences in adoption timing between family physicians and medical specialists.

March 8, 2012BMC Health Services ResearchOpen Access

Adoption of new drugs by physicians: a survival analysis

View Full Paper

Ask AI

Bookmark

Authors

AAAna Azparren IVIván Vergara BABorja Azaola

Discussion

Member takes

Overview

Observational study reveals faster adoption of newly launched pharmaceuticals among medical specialists compared to family physicians, highlighting critical windows for timely prescribing guidance.

Key Points

To evaluate the diffusion rate of eight newly launched drugs during their initial market phase and determine differences in adoption timing between family physicians and medical specialists.
Tracked 36 months of prescription registries following the launch of cefditoren, duloxetine, etoricoxib, ezetimibe, levocetirizine, olmesartan, pregabalin, and tiotropium.
Identified adopters as physicians with over 10 prescriptions whose prescribing volume exceeded the 25th percentile for each specialty tier.
Compared time to first prescription between family physicians and medical specialists using Kaplan-Meier survival curves.
Drug adoption across primary care displayed exponential growth that plateaued between month 6 and month 23 post-launch.
Tiotropium exhibited the fastest and widest diffusion, whereas cefditoren spread the slowest with the lowest adoption, and administrative hurdles initially delayed etoricoxib uptake.
Specialists adopted all eight drugs earlier than family physicians, who demonstrated a median adoption window of 4 to 6 months.

Cite This Study

Azparren et al. (2012) studied this question.

synapsesocial.com/papers/6ab38464e9857063ca8a231c https://doi.org/10.1186/1472-6963-12-56

View Full Paper

Ask AI

Bookmark

March 8, 2012BMC Health Services ResearchOpen Access

Adoption of new drugs by physicians: a survival analysis

View Full Paper

Ask AI

Bookmark

Authors

AAAna Azparren IVIván Vergara BABorja Azaola

Discussion

Member takes

Overview

Observational study reveals faster adoption of newly launched pharmaceuticals among medical specialists compared to family physicians, highlighting critical windows for timely prescribing guidance.

Key Points

To evaluate the diffusion rate of eight newly launched drugs during their initial market phase and determine differences in adoption timing between family physicians and medical specialists.
Tracked 36 months of prescription registries following the launch of cefditoren, duloxetine, etoricoxib, ezetimibe, levocetirizine, olmesartan, pregabalin, and tiotropium.
Identified adopters as physicians with over 10 prescriptions whose prescribing volume exceeded the 25th percentile for each specialty tier.
Compared time to first prescription between family physicians and medical specialists using Kaplan-Meier survival curves.
Drug adoption across primary care displayed exponential growth that plateaued between month 6 and month 23 post-launch.
Tiotropium exhibited the fastest and widest diffusion, whereas cefditoren spread the slowest with the lowest adoption, and administrative hurdles initially delayed etoricoxib uptake.
Specialists adopted all eight drugs earlier than family physicians, who demonstrated a median adoption window of 4 to 6 months.

Cite This Study

Azparren et al. (2012) studied this question.

synapsesocial.com/papers/6ab38464e9857063ca8a231c https://doi.org/10.1186/1472-6963-12-56

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark